Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV

Peregrine Acquires Worldwide Rights to Novel Anti-Angiogenesis Technology From M. D. Anderson Cancer Center

Peregrine Pharmaceuticals to Announce Fourth Quarter and Full Year FY 2007 Financial Results

Peregrine Pharmaceuticals Announces Registered Direct Offering of $22.5 Million in Common Stock

Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients

Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals Enters Into Development Collaboration with Dios Therapeutics

Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients

Peregrine Pharmaceuticals to Initiate New Bavituximab HCV Clinical Trial in Patients Co-Infected With HIV

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting